Qin Ning

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3366631/publications.pdf

Version: 2024-02-01

106 papers	10,870 citations	186265 28 h-index	98 g-index
107 all docs	107 docs citations	107 times ranked	23520 citing authors

#	Article	IF	CITATIONS
1	Experience-dependent associations between distinct subtypes of childhood trauma and brain function and architecture. Quantitative Imaging in Medicine and Surgery, 2022, 12, 1172-1185.	2.0	7
2	Twelve-Month Systemic Consequences of Coronavirus Disease 2019 (COVID-19) in Patients Discharged From Hospital: A Prospective Cohort Study in Wuhan, China. Clinical Infectious Diseases, 2022, 74, 1953-1965.	5.8	45
3	Abnormalities of Cortical Morphology and Structural Covariance Network in Patients with Subacute Basal Ganglia Stroke. Academic Radiology, 2022, 29, S157-S165.	2.5	3
4	Tractometryâ€Based Estimation of Corticospinal Tract Injury to Assess Initial Impairment and Predict Functional Outcomes in Ischemic Stroke Patients. Journal of Magnetic Resonance Imaging, 2022, 55, 1171-1180.	3.4	6
5	Insufficient immunity led to virologic breakthrough in NAs-treated chronic hepatitis B patients switching to Peg–IFN–ɑ. Antiviral Research, 2022, 197, 105220.	4.1	3
6	End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. Journal of Hepatology, 2022, 77, 42-54.	3.7	28
7	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduction and Targeted Therapy, 2022, 7, 57.	17.1	34
8	COVID-19 in China and the US: Differences in Hospital Admission Co-Variates and Outcomes. Vaccines, 2022, 10, 326.	4.4	0
9	Highâ€fatâ€induced nonalcoholic fatty liver potentiates vulnerability to and the severity of viral hepatitis in a <scp>C3H</scp> / <scp>HeN</scp> mouse model. BioFactors, 2022, 48, 216-227.	5.4	0
10	Complications of End-Stage Liver Disease: Advances from a Clinical Viewpoint. Infectious Diseases & Immunity, 2022, 2, 1-2.	0.6	0
11	Establishment and validation of a prognostic model for hepatitis B virusâ€′related acute-on-chronic liver failure patients with bacterial infection. Hepatology International, 2022, 16, 38-47.	4.2	7
12	Immunopathogenesis of patients with COVID-19: from the perspective of immune system  evolution' and  revolution'. Expert Reviews in Molecular Medicine, 2022, 24, e19.	3.9	3
13	Hepatic exosomes with declined <scp>MiR</scp> â€27bâ€3p trigger <scp>RIGâ€I</scp> / <scp>TBK1</scp> signal pathway in macrophages. Liver International, 2022, 42, 1676-1691.	3.9	3
14	A Comparative Study Between Tumor Blood Vessels and Dynamic Contrast-enhanced MRI for Identifying Isocitrate Dehydrogenase Gene 1 (IDH1) Mutation Status in Glioma. Current Medical Science, 2022, 42, 650-657.	1.8	3
15	Feasibility of a Clinical-Radiomics Model to Predict the Outcomes of Acute Ischemic Stroke. Korean Journal of Radiology, 2022, 23, 811.	3.4	18
16	Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p. Journal of Infectious Diseases, 2021, 223, 686-698.	4.0	24
17	Effects of childhood trauma experience and BDNF Val66Met polymorphism on brain plasticity relate to emotion regulation. Behavioural Brain Research, 2021, 398, 112949.	2.2	12
18	WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. Journal of Clinical Gastroenterology, 2021, 55, 1-11.	2.2	37

#	Article	IF	Citations
19	Intrauterine inflammation induced white matter injury protection by fibrinogen-like protein 2 deficiency in perinatal mice. Pediatric Research, 2021, 89, 1706-1714.	2.3	5
20	Impact of metabolic risk factors on the severity and outcome of patients with alcoholâ€associated acuteâ€onâ€chronic liver failure. Liver International, 2021, 41, 150-157.	3.9	13
21	The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study. Technology in Cancer Research and Treatment, 2021, 20, 153303382199781.	1.9	6
22	Venetoclax Combined with Hypomethylating Agents for Treatment-NaÃ-ve B/Myeloid Mixed Phenotype Acute Leukemia. Case Reports in Hematology, 2021, 2021, 1-4.	0.4	7
23	Combination Therapy. , 2021, , 319-338.		0
24	KCTD12 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. Translational Cancer Research, 2021, 10, 261-272.	1.0	1
25	An Online Questionnaire Survey on the Sexual Life and Sexual Function of Chinese Adult Men During the Coronavirus Disease 2019 Epidemic. Sexual Medicine, 2021, 9, 100293-100293.	1.6	39
26	Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A singleâ€arm, openâ€label, phase 3 trial. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2375-2382.	2.8	3
27	Therapeutic plasmaâ€exchange improves systemic inflammation and survival in acuteâ€onâ€chronic liver failure: A propensityâ€score matched study from AARC. Liver International, 2021, 41, 1083-1096.	3.9	25
28	Immunological Characteristics in Type 2 Diabetes Mellitus Among COVID-19 Patients. Frontiers in Endocrinology, 2021, 12, 596518.	3.5	30
29	Identification of hub genes and compounds controlling ovarian cancer stem cell characteristics via stemness indices analysis. Annals of Translational Medicine, 2021, 9, 379-379.	1.7	6
30	Pegylated Interferon-É' (IFN-É') Enhances the Inhibitory Effect of Natural Killer Cells on Regulatory T Cells via IFN-γ in Chronic Hepatitis B. Journal of Infectious Diseases, 2021, 224, 1878-1889.	4.0	8
31	Comprehensive Profiling Reveals Distinct Microenvironment and Metabolism Characterization of Lung Adenocarcinoma. Frontiers in Genetics, 2021, 12, 619821.	2.3	3
32	Clinical analysis and a novel risk predictive nomogram for 155 adult patients with hemophagocytic lymphohistiocytosis. Annals of Hematology, 2021, 100, 2181-2193.	1.8	6
33	Development and validation of an individualized immune prognostic model in stage l–III lung squamous cell carcinoma. Scientific Reports, 2021, 11, 12727.	3.3	12
34	Validation of non-invasive tools in predicting HBV-related acute-on-chronic liver failure. Hepatology International, 2021, 15, 571-574.	4.2	0
35	Molecular evidence suggesting the persistence of residual SARSâ€CoVâ€2 and immune responses in the placentas of pregnant patients recovered from COVIDâ€19. Cell Proliferation, 2021, 54, e13091.	5.3	12
36	Exploring the Immunopathogenesis of Pregnancy With COVID-19 at the Vaccination Era. Frontiers in Immunology, 2021, 12, 683440.	4.8	7

#	Article	IF	CITATIONS
37	Proton Pump Inhibitor Therapy Increases the Risk of Spontaneous Bacterial Peritonitis in Patients with HBV-Related Acute-on-Chronic Liver Failure. Advances in Therapy, 2021, 38, 4675-4694.	2.9	2
38	APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatology International, 2021, 15, 833-851.	4.2	43
39	Macrophage M1/M2 polarization dynamically adapts to changes in microenvironment and modulates alveolar bone remodeling after dental implantation. Journal of Leukocyte Biology, 2021, 110, 433-447.	3.3	22
40	Differences in Wall Shear Stress Between High-Risk and Low-Risk Plaques in Patients With Moderate Carotid Artery Stenosis: A 4D Flow MRI Study. Frontiers in Neuroscience, 2021, 15, 678358.	2.8	10
41	The Spatiotemporal Evolution of MRI-Derived Oxygen Extraction Fraction and Perfusion in Ischemic Stroke. Frontiers in Neuroscience, 2021, 15, 716031.	2.8	13
42	Biomimetic Lamellar Chitosan Scaffold for Soft Gingival Tissue Regeneration. Advanced Functional Materials, 2021, 31, 2105348.	14.9	28
43	The potential immune regulation benefit of CpAMs beyond HBV suppression. The Lancet Gastroenterology and Hepatology, 2021, 6, 680-682.	8.1	2
44	The Protective Benefit of Heme Oxygenase-1 Gene-Modified Human Placenta-Derived Mesenchymal Stem Cells in a N-Nitro-L-Arginine Methyl Ester-Induced Preeclampsia-Like Rat Model: Possible Implications for Placental Angiogenesis. Stem Cells and Development, 2021, 30, 991-1002.	2.1	6
45	Default Mode Network Alterations Induced by Childhood Trauma Correlate With Emotional Function and SLC6A4 Expression. Frontiers in Psychiatry, 2021, 12, 760411.	2.6	3
46	Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Letters, 2020, 471, 88-102.	7.2	229
47	A large realâ€world cohort study examining the effects of longâ€term entecavir on hepatocellular carcinoma and HBsAg seroclearance. Journal of Viral Hepatitis, 2020, 27, 397-406.	2.0	16
48	Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China. Hepatology International, 2020, 14, 723-732.	4.2	35
49	Effects of childhood trauma experience and COMT Val158Met polymorphism on brain connectivity in a multimodal MRI study. Brain and Behavior, 2020, 10, e01858.	2.2	2
50	Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission. Leukemia, 2020, 34, 2384-2391.	7.2	29
51	Familial Atrial Enlargement, Conduction Disorder and Symmetric Cardiac Hypertrophy Are Early Signs of PRKAG2 R302Q. Current Medical Science, 2020, 40, 486-492.	1.8	7
52	Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A singleâ€arm, openâ€label, phase 3 trial. Liver International, 2020, 40, 2685-2693.	3.9	9
53	Heme oxygenase-1 gene modified human placental mesenchymal stem cells promote placental angiogenesis and spiral artery remodeling by improving the balance of angiogenic factors in vitro. Placenta, 2020, 99, 70-77.	1.5	14
54	Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder. Theranostics, 2020, 10, 9702-9720.	10.0	41

#	Article	IF	CITATIONS
55	Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Critical Care, 2020, 24, 525.	5.8	125
56	Novel proton exchange rate MRI presents unique contrast in brains of ischemic stroke patients. Journal of Neuroscience Methods, 2020, 346, 108926.	2.5	8
57	Plasma perfusion combined with plasma exchange in chronic hepatitis B-related acute-on-chronic liver failure patients. Hepatology International, 2020, 14, 491-502.	4.2	9
58	Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1. Frontiers in Immunology, 2020, 11, 1366.	4.8	11
59	Age and anatomical location related hemodynamic changes assessed by 4D flow MRI in the carotid arteries of healthy adults. European Journal of Radiology, 2020, 128, 109035.	2.6	6
60	Hematological features of persons with COVID-19. Leukemia, 2020, 34, 2163-2172.	7.2	103
61	Risk factors for death in 1859 subjects with COVID-19. Leukemia, 2020, 34, 2173-2183.	7.2	105
62	Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ, The, 2020, 368, m1091.	6.0	3,061
63	Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients. Cellular and Molecular Immunology, 2020, 17, 878-880.	10.5	45
64	COVID-19 in persons with haematological cancers. Leukemia, 2020, 34, 1637-1645.	7.2	373
65	STING couples with PI3K to regulate actin reorganization during BCR activation. Science Advances, 2020, 6, eaax9455.	10.3	19
66	Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation, 2020, 130, 2620-2629.	8.2	3,820
67	Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1/PD-L1 in breast cancer. Aging, 2020, 12, 17305-17327.	3.1	14
68	Soluble fibrinogen-like protein 2 promotes the growth of hepatocellular carcinoma via attenuating dendritic cell-mediated cytotoxic T cell activity. Journal of Experimental and Clinical Cancer Research, 2019, 38, 351.	8.6	11
69	Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia–Pacific region. Hepatology International, 2019, 13, 695-705.	4.2	40
70	Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in		
	entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatology International, 2019, 13, 573-586.	4.2	29
71		2.0	29

#	Article	IF	CITATIONS
73	uNK cellâ€derived TGFâ€Î²1 regulates the long noncoding RNA MEG3 to control vascular smooth muscle cell migration and apoptosis in spiral artery remodeling. Journal of Cellular Biochemistry, 2019, 120, 15997-16007.	2.6	17
74	Roadmap to functional cure of chronic hepatitis B: An expert consensus. Journal of Viral Hepatitis, 2019, 26, 1146-1155.	2.0	57
75	Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 127-134.	8.1	83
76	Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1168-1176.	2.8	17
77	Inhibiting trophoblast PAR-1 overexpression suppresses sFlt-1-induced anti-angiogenesis and abnormal vascular remodeling: a possible therapeutic approach for preeclampsia. Molecular Human Reproduction, 2018, 24, 158-169.	2.8	10
78	Conditioned Medium from Human Umbilical Vein Endothelial Cells Promotes Proliferation, Migration, Invasion and Angiogenesis of Adipose Derived Stem Cells. Current Medical Science, 2018, 38, 124-130.	1.8	10
79	î³Î´T Cells Contribute to the Outcome of Murine Fulminant Viral Hepatitis via Effector Cytokines TNF-α and IFN-γ. Current Medical Science, 2018, 38, 648-655.	1.8	8
80	Notch1 Impairs Endothelial Progenitor Cell Bioactivity in Preeclampsia. Reproductive Sciences, 2017, 24, 47-56.	2.5	10
81	dNK derived IFN- \hat{l}^3 mediates VSMC migration and apoptosis via the induction of LncRNA MEG3: A role in uterovascular transformation. Placenta, 2017, 50, 32-39.	1.5	42
82	Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. Liver International, 2017, 37, 1497-1507.	3.9	24
83	Systemic inflammatory response syndrome in acuteâ€onâ€chronic liver failure: Relevance of †golden window': A prospective study. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1989-1997.	2.8	53
84	HOXA9 transcriptionally regulates the EPHB4 receptor to modulate trophoblast migration and invasion. Placenta, 2017, 51, 38-48.	1.5	9
85	Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection. Antiviral Research, 2017, 147, 75-85.	4.1	11
86	Functional restoration of CD56bright NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B. Hepatology International, 2017, 11, 419-428.	4.2	12
87	Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome. Journal of Infectious Diseases, 2017, 216, S771-S777.	4.0	30
88	Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1-year follow-up of the OSST study. Antiviral Therapy, 2016, 21, 337-344.	1.0	37
89	Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. Journal of Hepatology, 2016, 65, 674-682.	3.7	36
90	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut, 2016, 65, 313-320.	12.1	112

#	Article	IF	Citations
91	Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir suppressed patients with CHB. Antiviral Therapy, 2015, 20, 591-602.	1.0	25
92	Definition of ACLF and inclusion criteria for extra-hepatic organ failure. Hepatology International, 2015, 9, 360-365.	4.2	19
93	An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: The future of chronic hepatitis B?. Journal of Hepatology, 2015, 62, 240-241.	3.7	17
94	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatology International, 2014, 8, 453-471.	4.2	861
95	Distribution and clinical correlates of viral and host genotypes in <scp>C</scp> hinese patients with chronic hepatitis <scp>C</scp> virus infection. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 545-553.	2.8	113
96	Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma. Hepatology International, 2014, 8, 567-575.	4.2	26
97	Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM model. Hepatology International, 2014, 8, 64-71.	4.2	27
98	Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial). Journal of Hepatology, 2014, 61, 777-784.	3.7	198
99	Combined Adenovirus-Mediated Artificial microRNAs Targeting mfgl2, mFas, and mTNFR1 Protect against Fulminant Hepatic Failure in Mice. PLoS ONE, 2013, 8, e82330.	2.5	16
100	CD4–CD8-T cells contribute to the persistence of viral hepatitis by striking a delicate balance in immune modulation. Cellular Immunology, 2012, 280, 76-84.	3.0	9
101	Contribution of IL-17 to mouse hepatitis virus strain 3-induced acute liver failure. Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32, 552-556.	1.0	6
102	Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model. Hepatology International, 2012, 6, 735-743.	4.2	31
103	Liver TCRγδ+ CD3+ CD4â´' CD8â´' T cells contribute to murine hepatitis virus strain 3-induced hepatic injury through a TNF-α-dependent pathway. Molecular Immunology, 2012, 52, 229-236.	2.2	19
104	Increased Killing of Liver NK Cells by Fas/Fas Ligand and NKG2D/NKG2D Ligand Contributes to Hepatocyte Necrosis in Virus-Induced Liver Failure. Journal of Immunology, 2010, 184, 466-475.	0.8	121
105	Fulminant viral hepatitis: molecular and cellular basis, and clinical implications. Expert Reviews in Molecular Medicine, 2001 , 3 , $1-19$.	3.9	47
106	240â€week Entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C. Journal of Viral Hepatitis, 0, , .	2.0	1